20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Waltham, Massachusetts-based TESARO has an approved product in Varubi (rolapitant) for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. The company is also developing its Phase 3 asset, niraparib, a PARP inhibitor in ovarian and breast cancer indications.
Tesaro said it would file NDA and MAA for all patients with recurrent, platinum-sensitive ovarian cancer in the fourth quarter 2016.
Further, the brokerage said the recent ESMO conference shows Niraparib has broad effects across the second-line ovarian cancer population and expects the labeling to likewise be broad.
On the M&A front, the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily) given high demand for late stage oncology assets, especially in the PARP space due to its potential for activity across a range of tumors.
"Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0 percent POS for now but we conservatively see at least another $1 billion in sales from PARP expansion," analyst Alethia Young wrote in a note.
"For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50–75 percent and R&D synergies of 15–30 percent. In our base case TSRO P&L we model a tax rate of 30 percent so there could be synergies here as well," Young added.
Young also sees further upside to valuation in the long-term from:
- "PARP expansion in other platinum sensitive tumors."
- "Potential HRD- sales in 1L as we expect the company will amend the protocol."
- "Readouts in breast cancer PARP studies in '17."
- "Immuno-oncology where we expect early data over 2017."
At the time of writing, shares of Tesaro had surged 22.58 percent on the day to $121.69 after setting a new 52-week high of $118.80.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!